Rat ob-receptors and nucleotides encoding them

Information

  • Patent Grant
  • 6281346
  • Patent Number
    6,281,346
  • Date Filed
    Thursday, February 20, 1997
    27 years ago
  • Date Issued
    Tuesday, August 28, 2001
    23 years ago
Abstract
The rat ob receptor gene has been isolated and cloned. Two different alleles have been identified: the wild-type, and the fa-allele which differs from the wild type by only one base pair. The base pair change, however introduces an MspI restriction site into the DNA sequence, and also results in an amino acid change. Also part of the invention are the receptors, vectors containing the nucleic acid encoding the receptors, host cells transformed with this gene, and assays which use the gene or protein and identify new ligands.
Description




FIELD OF THE INVENTION




This invention relates to rat ob receptor proteins, to DNA and RNA sequences encoding them, and to assays using rat receptor proteins.




BACKGROUND OF THE INVENTION




Recently the identification of mutations in several genes involved in the onset of obesity in rodents have been identified. Of particular interest are mutations discovered in the peptide hormone, leptin, which is a component of a novel signal transduction pathway that regulates body weight (Zhang et al. 1994,


Nature


372:425-432; Chen et al. 1996,


Cell


84:491-495). Leptin was initially discovered by the positional cloning of the obesity gene, ob, in mice. Two different ob alleles have been identified: one mutation causes the premature termination of the leptin peptide resulting in a truncated protein, and the other mutation changes the transcriptional activity of the obesity (ob) gene, resulting in a reduced amount of circulating leptin.




There is a correlation between a decrease in the levels of biologically active leptin and the overt obese phenotype observed in ob/ob mice. Recombinant leptin has been shown to induce weight loss in the ob/ob mouse but not in the diabetic phenotype db/db mouse (Campfield et al. 1995,


Science


269: 546-549; Halaas et al. 1995,


Science


269: 543-546; Pellymounter et al. 1995,


Science


269:540-543; Rentsch et al. 1995,


Biochem. Biophys. Res. Comm.


214:131-136; and Weigle et al. 1995,


J. Clin. Invest.


96:2065-2070).




Although the synthesis of leptin occurs in the adipocyte, its ability to decrease food intake and increase metabolic rate appears to be mediated centrally by the hypothalamus. Injection of recombinant leptin into the third ventricle of the brain elicits a similar response as peripheral administration of leptin. Furthermore, the recent cloning of the human receptor for the leptin, the ob-receptor (OB-R), reveals that it is transcribed in the hypothalamus (Tartaglia et al. 1995, Cell 83:1263-1271; Stephens et al. 1995,


Nature


377: 530-532). In addition, a mutation that results in premature termination of the long-form of the mouse OB-R, which is preferentially expressed in the hypothalamus, appears to be responsible for the obese phenotype of the db/db mouse (Lee et al. 1996,


Nature


379:632-635; Chua et al. 1996,


Science


271:994-996; and Chen et al. 1996,


Cell


84:491-495).




The fa mutation is a recessive allele that arose spontaneously in the 13M rat strain and was first reported in 1961 (Zucker et al. 1961,


J. Heredity


52: 275-278. The onset of obesity in the fa/fa Zucker rat is at 5-7 weeks of age and progresses with age. The mature fatty rat is approximately twice the weight of lean litter mates and over 40% of its body weight is adipose tissue (Zucker et al. 1962,


Proc. Soc. Exp. Biol. Med.


110:165-171; Zucker et al. 1963,


J. Nutrition


80:6-19). The fa/fa Zucker rat exhibits hypercholesterolemia, hyperlipemia, and hyperglycemia and has been used extensively as an animal model for human cardiovascular disease and diabetes. Most of the fatty Zucker rat colonies have been maintained by outbreeding in order to retain heterozygousity at as many loci as possible. However, certain stocks have been inbred to produce animals such as the Zucker diabetic fatty (ZDF) rat which exhibits a more profound diabetic phenotype than the outbred fa/fa Zucker rat (Clark, et al. 1983,


Proc. Soc. Exp. Biol. Med.


173: 68-75).




The fa mutation maps to rat chromosome 5 in a region that is syntenic with the db allele on mouse chromosome 4 (Truett, et al. 1991,


Proc. Natl. Acad. Sci.


88: 7806-7809). This observation, in conjunction with the similar phenotypes of the fa/fa rat and the db/db mouse, led to the proposal that the fa gene was the rat homologue of the db gene. Higher resolution genetic mapping supports the contention that the fa mutation is located in the gene encoding the rat OB-R (Chua et al.


Science


271: 994).




It would be desirable to be able to further experiment with the rodent model system for obesity, and to be able to clone and produce purified rat ob receptor to use in assays for the identification of ligands which may be useful in understanding obesity and for its prevention and treatment.




DETAILED DESCRIPTION OF THE INVENTION




This invention relates to a rat ob receptor which is substantially free from associated rat membrane proteins. It also relates to substantially purified rat ob receptor (“rat OB-R” or “rat OB-receptor”) protein. One of the rat OB-Rs of this invention is obtained from a rat which has a wild-type OB-R. Another rat OB-R of this invention is obtained from a rat which has the fa mutation.




Another aspect of this invention is to nucleic acids which encode a rat OB receptor. The nucleic acid may be any nucleic acid which can encode a protein, such as genomic DNA, cDNA, or any of the various forms of RNA. Preferably, the nucleic acid is cDNA.




This invention also includes vectors containing a rat OB-R gene, host cells containing the vectors, and methods of making susbstantially pure rat OB-R protein comprising the steps of introducing a vector comprising a rat OB-R gene into a host cell, and cultivating the host cell under appropriate conditions such that rat OB-R is produced. The rat OB-R so produced may be harvested from the host cells in conventional ways.




Yet another aspect of this invention are assays which employ a rat OB-R. In these assays, various molecules, suspected of being rat OB-R ligands are contacted with a rat OB-R, and their binding is detected. In this way agonists, antagonists, and ligand mimetics may be identified. A further aspect of this invention are the ligands so indentified.











BRIEF DESCRIPTION OF THE FIGURES





FIGS. 1A-1B

illustrate the amino acid sequence of the rat OB-receptor.





FIGS. 2A-2F

illustrate the cDNA sequence of the rat OB receptor.





FIGS. 3A-3C

illustrate a table of primers used for the PCR reactions detailed in the Examples.





FIGS. 4A-4B

illustrate the gels demonstrating the analysis of the A


880


to C mutation identified in the OB-receptor from hypothalamic cDNA and genomic DNA obtained from lean and fa/fa rats.





FIG. 5

compares the amino acid sequence between human cytokine receptor gp130 (Humgp 130), the mouse OB-R (MousOBR), human OB-R (HumOBR) and lean rat OB-R (RatOBR). The numbering refers to the location in the protein, and the cytokine motif GXWSXWS (SEQ ID NO:66) can be seen.











As used througout the specification and claims, the following definitions apply:




“Substantially free from associated rat membrane proteins” means that the rat receptor protein is not in physical contact with any rat membrane proteins.




“Substantially purified rat OB-receptor” means that the rat receptor protein is at least 90% and preferably at least 95% pure.




“Wild type” means that the gene or protein is substantially the same as that found in a rat which is not considered to have a mutation for that gene or protein. It is also referred to as “lean” throughout the specification and claims.




“fa” means that the gene or protein is substantially the same as that found in a rat homologous for the fatty mutation.




“Substantially the same” when referring to a nucleic acid or amino acid sequence means either it is the same as the reference sequence, or if not exactly the same, contains changes which do not affect its biological activity or function. Although the fa and wild type rat OB-R genes differ by only one nucleotide, they are not considered “substantially the same” as the biological activity and functions of their encoded proteins are very different.




The rat OB-R is a member of the cytokine receptor family. Motifs that are characteristic of the cytokine receptors such as the motif WSXWS (SEQ ID NO:67 W is the amino acid residue tryptophan, S is the amino acid residue serine and X is any amino acid.) were found to be conserved in the rat OB-R.




One aspect of this invention is the molecular cloning of a rat OB-R. The nucleotide sequence for the rat OB-R from both lean and fa/fa rat hypothalamic cDNA was determined and compared. In the fa/fa rat, there was a single nucleotide change, an A to C at nucleotide 880 resulting in an amino acid change at glutamine 269 to proline. The mutation introduces an Msp I site (CCGG) that was utilized to genotype a number of lean control and fatty animals. The results indicate that the mutation is tightly linked to the fa allele. Thus, it is likely that the fa mutation lies in the OB-R receptor cDNA and that the A to C transversion at base pair 880 is responsible for the obese phenotype. Both rat OB-R alleles, i.e. the OB-R containing a glutamine 269 and the allele containing proline 269 are part of this invention, as are all nucleic acids which can encode them.




The nucleotide sequence of the wild type rat OB-R cDNA obtained in accordance with this invention has 3650 nucleotides, as shown in

FIGS. 2A-2F

. This DNA sequence contains an open reading frame from nucleotide 75 to 3563 that encodes a protein of 1162 amino acids. The open reading frame extending from nucleotide 75 to 3563 makes up one aspect of this invention.




The wild type and fa receptor proteins contain an extracellular, a transmembrane domain and a cytoplasmic domain. The extracellular domain extends from amino acids 1-830; the transmembrane domain is from amino acids 839-860; and the cytoplasmic domain is from amino acids 860-1162. This invention also includes proteins which lack one or more of these domains. Such deleted proteins are useful in assays for identifying ligands and their binding activity.




It has also been found that alternate splicing can occur in the receptor gene processing. This can occur at base pair 2742 (lysine


889


). The alternative sequence (for both the wild type and fa) genes and receptors (SEQ ID Nos: 68 and 69, respectively) is shown below and forms another aspect of this invention:














AGA GCG GAC ACT CTT TGA ATA TCT







  R   A   D   T   L   STOP











Amino acids 1-28 form a signal sequence; thus the mature proteins extend from amino acids 28-1162. The mature proteins form yet another aspect of this invention. This differs from the signal sequence of 1-22 reported for mouse and human OB-r; this may be explained by the use of a different analysis program.




Comparison of wild type rat OB-R to known OB-R receptors of different species has revealed some similarities. For example, the rat OB-R nucleotide sequence is 93% identical to the mouse OB-R and 81% identical to the human OB-R sequences. The deduced amino acid sequence of the rat OB receptor is 93% identical to the mouse and 76% identical to the human OB-R.




The size of the open reading frame of the rat OB-receptor of this invention, (1162 amino acids) is similar to that of the human OB-R (1165 amino acids) reported by Toriaglla et al. 1995,


Cell


83:1-20. Both the rat OB-R of this invention and the human OB-R contain a large cytoplasmic domain. In contrast, the mouse OB-receptor of 894 amino acids has a relatively short cytoplasmic domain.




One of the most notable and surprising aspects of this invention is that there is only a single nucleotide difference between the wild type rat cDNA and the fa/fa rat cDNA for the OB-R. PCR fragments obtained from fa/fa cDNA were sequenced. A single nucleotide change relative to the lean cDNA sequence was observed in the hypothalamus. An A to C transversion at bp 880 results in an amino acid change of glutamine to proline at amino acid residue 269. Every tissue examined in the fa/fa rat was found to be homozygous for this A to C mutation at nucleotide 880. The A to C change in the sequence introduces a MspI restriction endonuclease site (CCGG) into the sequence, and this is the basis of an assay for presence of the mutation.




Thus another aspect of this invention is an assay to determine the genotype of a OB-R DNA, suspected of having an A to C mutation at bp 880, comprising digesting the OB-R DNA with MspI, and comparing the restriction products so producted. In a preferred embodiment, the assay comprises generating PCR products of the OB-R DNA, digesting the PCR products with MspI, and comparing the restriction products so produced with those obtained from a rat containing a wild-type OB-R gene. The gene from a rat which has a wild-type OB-R will yield two restriction products, 1774 and 289 bp long. The gene from the fa rat will have three restriction products: 747, 1027 and 289 bp long. These are easily observed using standard gel techniques.




The OB-R gene can be introduced into virtually any host cell using known vectors. Preferred host cells include


E. coli


as well as mammalian and yeast cell lines.




One of ordinary skill in the art is able to choose a known vector which is appropriate for a given host cell; generally plasmids or viral vectors are preferred. The OB-R gene may be present in the vector in its native form, or it may be under the control of a heterologous promoter, and if desired, one or more enhancers, or other sequences known to regulate transcription or translation. The host cell containing the OB-R gene is cultured, and the OB-R gene is expressed. After a suitable period of time the OB-R protein may be harvested from the cell using conventional separation techniques.




A further aspect of this invention is the use of rat OB-R in assays to identify OB-R ligands. A ligand binds to the OB-R, and in vivo may or may not result in an activation of the receptor. Ligands may be agonists of the receptor (i.e. stimulate its activity), antagonists (inhibit its activity) or they may bind with little or no effect upon the receptor activity.




In an assay for ligands, the rat OB-R of this invention is exposed to a putative ligand, and the amount of binding is measured. The amount of binding may be measured in many ways; for example, a ligand or the OB-R being investigated may be labeled with a conventional label (such as a radioactive or fluorescent label) and then put in contact with the OB-R under binding conditions. After a suitable time, the unbound ligand is saparated from the OB-R and the amount of ligand which has bound can be measured. This can be performed with either the wild-type OB-R or the fa OB-R of this invention; alternatively the amount of binding to the two alleles can be compared. In a competitive assay, both the putative ligand and a known ligand are present, and the amount of binding of the putative ligand is compared to the amount of binding to a known ligand. Alternatively, the putative ligand's ability to displace previously bound known ligand (or vice-versa) may be measured. In yet other embodiments, the assay may be a heterogeneous one, where the OB-R may be bound to a surface, and contacted with putative ligands. Dectection of binding may be by a variety of methods, including labelling, reaction with antibodies, and chomophores.




The following non-limiting Examples are presented to better illustrate the invention.




EXAMPLE 1




Preparation of mRNA and cDNA From Rat Tissues




Tissues were collected from lean and fa/fa Zucker rats and snap frozen in liquid nitrogen. The tissues collected included: hypothalamus, pituitary, lung, liver, kidney, heart, adrenal glands, smooth muscle, skeletal muscle, and adipose tissue. The tissues were homogenized with a Brinkmann Polytron homogenizer in the presence of guanadinium isothiocyanate. mRNA was prepared from hypothalamus, lung, and kidney according to the instructions provided with the messenger RNA isolation kit (Stratagene, La Jolla, Calif.). cDNA was prepared from approximately 2 μg of mRNA with the SuperScript™ choice system (Gibco/BRL Gaithersburg, Md.). The first strand cDNA synthesis was primed using 1 ug of oligo(dT)12-18 primer and 25 ng of random hexamers per reaction. Second strand cDNA sythesis was performed according to the manufacturer's instructions. The quality of the cDNA was assessed by labeling an aliqout ({fraction (1/10)}


th


) of the second strand reaction with approximately 1 μCi of [a-


32


P]dCTP (3000 Ci/mmol). The labeled products were separated on an agarose gel and detected by autoradiography.




EXAMPLE 2




Amplification of Lean Rat OB-receptor cDNA using PCR




The initial portion of the rat OB receptor was obtained by PCR using degenerate primers based on the mouse and human OB-receptor amino acid sequences. A set of 9 oligonucleotide primers, ROBR 1-9, shown in

FIG. 3A-3C

, were designed to regions with low codon degeneracy. The pairing of the forward primers ROBR 2 (′5-CAY TGG GAR TTY CTI TAY GT-3′) and ROBR 3 (5′-GAR TGY TGG ATG AAY GG-3′), SEQ ID NOs:4 and 5, respectively, corresponding to mouse amino acid sequences HWEFLYV and ECWMKG(SEQ ID NOs: 70 and 71, respectively), with reverse primers ROBR 6 (5 ′-ATC CAC ATI GTR TAI CC-3′), 7(5′-CTC CAR TTR CTC CAR TAI CC-3′), and 8 (5′-ACY TTR CTC ATI GGC CA-3′), SEQ ID NOs:8-10, respectively, representing mouse amino acids, GYTMWI, VYWSNWS, and WPMSKV, (SEQ ID NOs:72-74) respectively) provided good yields of the appropriately sized products. The fragments of interest were amplified as long polymerase chain reaction (PCR) products by a modifying of the method of Barnes (1994,


Proc. Natl. Acad. Sci.


91:2216-2220, which is hereby incorporated by reference. In order to obtain the required long PCR fragments, Taq Extender (Stratagene, La Jolla Calif.) and the Expand Long Template PCR System (Boehringer Mannheim, Indianapolis, Ind.) were used in combination. The standard PCR reaction mix, in a final volume of 20 μl, contained 5 ng of template (lean rat cDNA), 100 ng of primers, 500 μM dNTPs, 1×Buffer 3 from the Expand kit, 0.1 μl each of Taq Polymerase and Taq Expander. Reactants were assembled in thin walled reaction tubes. The amplification protocol was 1 cycle of 92° C. for 30 sec., followed by 32 cycles at 92° C. for 30 sec., 45° C. for 1 min. and 68° C. for 3 min. using a Perkin-Elmer (Norwalk, Conn.) 9600 Thermal Cycler.




This strategy produced a series of PCR products with the largest being approximately 2.2 Kbp amplified from primers ROBR 2 and ROBR 8. These products were subcloned for DNA sequence analysis as described below.




EXAMPLE 3




Subcloning of PCR Products




PCR products of the appropriate size were prepared for subcloning by separation on an agarose gel, excising the band, and extracting the DNA using Prep-A-Gene (BioRad, Richmond, Calif.). PCR products were ligated into pCR™II (Invitrogen, San Diego, Calif.) according to the instructions provided by the manufacturer. The ligation was transformed into INVaF cells and plated on Luria-Bertani plates containing 100 μg/ml ampicillin and X-Gal (32 μl of 50 mg/ml X-Gal (Promega, Madison, Wis.). White colonies were picked and grown overnight in Luria -Bertani broth plus 100 μg/ml ampicillin. Plasmid DNAs were prepared using the Wizard miniprep kit (Promega, Madison, Wis.). Inserts were analyzed by digesting the plasmid DNA with EcoRI and separating the restriction endonulease digestion products on an agarose gel.




Plasmid DNA was prepared for DNA sequencing by ethanol precipitation and resuspending in water to achieve a final DNA concentration of 100 μg/ml. DNA sequence analysis was performed using the ABI PRISM™ dye terminator cycle sequencing ready reaction kit with AmpliTaq DNA polymerase, FS. The initial DNA sequence analysis was performed with M13 forward and reverse primers, subsequently primers based on the rat OB-R sequence were utilized. Following amplification in a Perkin-Elmer 9600, the extension products were purified and analyzed on an ABI PRISM 377 automated sequencer (Perkin Elmer, Norwalk, Conn.). DNA sequence data was analyzed with the Sequencher program. Due to the unknown genotype of the lean Zucker rat for the fa allele, either (+/+ or +/fa) the DNA sequence of multiple subclones of each fragment was analyzed to determine the cDNA sequence of the lean rat OB-R.




EXAMPLE 4




Amplification and DNA Sequence Analysis of Lean and fa/fa With Primers ROBR 10 and 17




Once specific lean rat sequence had been obtained from the ROBR 2-8 PCR fragment, rat specific primers ROBR 10 (5′-CTG CAC TTA ACC TGG CCT ATC-3′) and ROBR 17 (5′-GGC CAG AAC TGT AAC AGT GTG-3′), SEQ ID Nos:12 and 19, respectively, were synthesized. Using primers ROBR 10 and 17, PCR products were amplified from rat lean hypothalamus, lean lung, fa/fa hypothalamus and fa/fa kidney cDNAs. The PCR conditions used for this reaction were a PCR reaction mix with a total volume of 50 μl containing 5 ng of template (various rat cDNAs mentioned above), 200 ng of primers, 500 μM dNTPs, 1×Buffer 3 from the Expand kit, 0.25 μl each of Taq Polymerase and Taq Expander. Reactants were assembled in thin walled reaction tubes. The amplification protocol was 1 cycle of 92° C. for 30 sec., followed by 32 cycles at 92° C. for 30 sec., 60° C. for 1 min. and 68° C. for 4 min. using a Perkin Elmer 9600 Thermal Cycler.




EXAMPLE 5




Amplification of the 3′ Portion of the Rat OB-R cDNA using Semi-nested PCR




The 3′ end of both the lean and fa/fa rat OB-receptors was obtained by the PCR with an initial amplification of the rat cDNA using a rat specific 5′ primer paired with either a degenerate primer that corresponds to the cytoplasmic domain of the human OB-receptor or the 3′ UTR of the human or mouse sequences. This was followed by a second short round of amplification with either one of the original primers paired with a nested primer positioned within the originally amplified fragment, or with two nested primers.




Rat specific primers ROBR 15 (5′-TCA CCT TGC TTT GGA AGC C-3′), ROBR 16 (5′-GAC ATG GTC ACA AGA TGT GGG-3′) and ROBR 23 (5′-CCT GGA CAC TGT CAC CTG ATG-3′), SEQ ID NOs:17, 18 and 25, respectively, were paired in different combinations with human degenerate primers located in the cytoplasmic domain of the human OB receptor, HOBR 5 (5′-CAT CAT YTC RTC YTT RTT YTT CCA-3′), HOBR 6 (5′-GTY TGR AAY TGI GGC AT-3′) and HOBR 7 (5′-TCR CAC ATY TTR TTY TCC AT-3′), SEQ ID NOs:53-55, respectively, which correspond to amino acids WKNKDEMM, MPQFQT, and MENKMCD, SEQ ID NOs:75-77 respectively. Primers from the 3′ ends of the human, HOBR 1R (5′-TCT CTC CCA CCC ACA ACT AT-3′), SEQ ID NO:52 and mouse, MOBR 1R (5′-TGG GTT CAT CTG TAG TGG TC-3′),SEQ ID NO:57 OB receptors were also paired with rat specific primers.




PCR reactions were performed with various combinations of the above primer sets in a total volume of 20 μl containing 5 ng of template (lean and fa/fa hypothalamus cDNAs), 100 ng of primers, 500 μM dNTPs, 1×Buffer 3 from the Expand kit, 0.1 μl each of Taq Polymerase and Taq Expander. Reactants were assembled in thin walled reaction tubes for the Perkin Elmer 9600 Thermal cycler. The amplification protocol was 1 cycle of 92° C. for 30 sec., followed by 32 cycles at 92° C. for 30 sec., 45° C. for 1 min. and 68° C. for 4 min. using a Perkin Elmer 9600 Thermal Cycler.




Products were then purified, removing all nucleotides and primers, using the QIAquick PCR purification kit according to the manufacturer's specified protocols and resuspended in 30 μl of water. The second PCR step was then performed using the first PCR reaction as the template and a nested rat specific primer paired with the original 3′ primer as outlined above. The reaction conditions were a 50 μl reaction containing 5 μl of template (from the purified PCR product), 200 ng of primers, 500 μM dNTPs, 1×Buffer 3 from the Expand kit, 0.25 μl each of Taq Polymerase and Taq Expander. Reactants were assembled in thin walled reaction tubes for the Perkin Elmer 9600 Thermal cycler. The amplification protocol was 1 cycle of 92° C. for 30 sec., followed by 25 cycles at 92° C. for 30 sec., 45° C. for 1 min. and 68° C. for 4 min. using a Perkin Elmer 9600 Thermal Cycler.




The largest fragment that was generated using the strategy was a fragment produced from ROBR 16 and HOBR 1R that was approximately 1500 bp in length. The mouse 3′ UTR which presumably encodes a smaller isoform generated by alternative splicing, produced a fragment that was about 650 bp long.




EXAMPLE 6




Amplification of 5′ End of the Rat OB Receptor




The 5′ end of the rat OB receptor was obtained by using semi-nested PCR in a manner analogous to that described above for the 3′ end. In this case the rat specific primers are the 3′ primers that were combined with primers from the 5′ UTRs of the human OB-receptor. The primers utilized were HOBR 1F (5′-CTT ATG CTG GGA TGT GCC-3′), SEQ ID NO:50, and HOBR 1F-2 (5′-TCG TGG CAT TAT CCT TCA G-3′) paired with either ROBR 11 (5′-GAT AGG CCA GGT TAA GTG CAG-3′), SEQ ID NO:13, or ROBR 12 (5′-GAG TGC GGA GCA GTT TTG AC-3), SEQ ID NO:14. The largest product, HOBR 1F-2 and ROBR 11, yielded a 500 bp fragment that covers the region and induces an initiator methionine codon.




EXAMPLE 7




Identification of a Nucleotide Change in the fa/fa cDNA




PCR fragments obtained from fa/fa cDNA were prepared for DNA sequence analysis by separating the PCR products on an agarose gel, excising the band of interest, and extracting the DNA using Prep-A-Gene (BioRad). Sequencing results of the PCR product generated from fa/fa hypothalamic cDNA identified a single nucleotide change relative to the lean cDNA sequence. An A to C transversion at bp 880 results in an amino acid change of glutamine to proline at amino acid residue 269. The A to C change in the sequence introduces a MspI restriction endonuclease site (CCGG) into the sequence.




Several independent PCR products were amplified from hypothalamus, lung and kidney cDNA from lean and fa/fa tissues using the primer pair ROBR 10 and 17. This product contains only one endogenous Msp I site at nucleotide 1907. Restriction digestion of the PCR products in a reaction that consisted of 5 μl of the PCR reaction, 4 μl of water and 1 μl of the restriction endonuclease Msp I. These were mixed, incubated for 1 hr at 37° C. and analyzed on a 1% agarose gel. The PCR products from the lean rat cDNAs contained only the endogenous Msp I site and generated products of 1774 and 289 bp. In contrast the PCR products from the fa/fa cDNAs contained an additional Msp I site identified during the sequencing of ROBR 10/17 and generated products of 747, 1027, and 289. Thus, every tissue examined in the fa/fa rat was homozygous for the A to C mutation at nucleotide 880.




EXAMPLE 8




Genotype Analysis of Lean and Fa/fa Rats




Genomic DNA was prepared from a 2 cm portion of the tail from ten lean and ten fa/fa Zucker rats and 2 lean and 5 fa/fa ZDF rats. The tissue was digested overnight at 55° C. using 0.3 μg of Proteinase K in 0.7 ml buffer containing 50 mM Tris, pH 8.0, 100 mM EDTA, and 0.5% SDS. The DNA was extracted two times with phenol/chloroform and one time with chloroform. The DNA was precipitated by adding NaCl to achieve a concentration of 0.3M and then adding an equal volume of 100% ethanol. The DNA was transferred to a 70% wash and then resuspended in 10 mM Tris, 1 mM EDTA.




Genomic DNA, obtained as outlined above from various sources, was diluted in water to a final concentration of approximately 100 ng/ul. In this experiment, the reaction conditions were a 20 μl reaction containing 1 μl of genomic DNA template, 100 ng of primers, 500 μM dNTPs, 1×Buffer 3 from the Expand kit, 0.25 μl each of Taq Polymerase and Taq Expander. Reactants were assembled in Perkin Elmer 0.5 ml thin walled reaction tubes. The amplification protocol for a Perkin Elmer 480 Thermal Cycler was 32 cycles of 92° C. for 30 sec., 54° C. for 1 min. and 68° C. for 5 min. Primers ROBR 27 (5′-GTT TGC GTA TGG AAG TCA CAG-3′), SEQ ID NO:29, and ROBR 28 (5′-ACC AGC AGA GAT GTA TCC GAG-3′), SEQ ID NO:30, were used to amplify a 1.8 Kbp fragment that must contain approximately 1.65 Kbp of intronic sequence since these primers only produce a 156 bp PCR fragment when amplifying cDNA.




After PCR amplification, an Msp I restriction endonuclease digestion of the products was undertaken. The reaction contained 5 μl of the PCR reaction, 4 μl of water and 1 μl of the restriction endonuclease Msp I. These were mixed and incubated for 1 hr at 37° C. The products were then analyzed on a 1% agarose gel. The PCR products contained an endogenous Msp I site that cleaves the fragment somewhere in the intron and produces a 700 bp fragment. Thus, the Msp I restriction endonuclease digestion of the 1800 bp ROBR 27/28 PCR product from a homozygous lean rat yields two fragments of 1100 bp and the endogenous 700 bp fragment. In contrast, Msp I digestion of PCR products from a fa/fa ROBR 27/28 PCR amplification, which contains the A to C mutation, introduces an additional Msp I site that cleaves the 1100 bp band to produce a 950 bp and a small fragment of 130 bp. The genomic analysis of the lean Zucker and ZDF rats also demonstrated that Fa/fa heterozygotes where present as illustrated by Msp I restriction endonuclease digestion patterns that showed that these rats had the 1100 bp fragments as well as the 950 mutant fragment.







77





1162 amino acids


amino acid


single


linear




protein




not provided



1
Met Thr Cys Gln Lys Phe Tyr Val Val Leu Leu His Trp Glu Phe Leu
1 5 10 15
Tyr Val Ile Thr Ala Leu Asn Leu Ala Tyr Pro Thr Ser Pro Trp Arg
20 25 30
Phe Lys Leu Phe Cys Ala Pro Pro Ser Thr Thr Asp Asp Ser Phe Leu
35 40 45
Ser Pro Ala Gly Val Pro Asn Asn Thr Ser Ser Leu Lys Gly Ala Ser
50 55 60
Glu Ala Leu Val Glu Ala Lys Phe Asn Ser Thr Gly Ile Tyr Val Ser
65 70 75 80
Glu Leu Ser Lys Thr Ile Phe His Cys Cys Phe Gly Asn Glu Gln Gly
85 90 95
Gln Asn Cys Ser Ala Leu Thr Gly Asn Thr Glu Gly Lys Thr Leu Ala
100 105 110
Ser Val Val Lys Pro Leu Val Phe Arg Gln Leu Gly Val Asn Trp Asp
115 120 125
Ile Glu Cys Trp Met Lys Gly Asp Leu Thr Leu Phe Ile Cys His Met
130 135 140
Glu Pro Leu Leu Lys Asn Pro Phe Lys Asn Tyr Asp Ser Lys Val His
145 150 155 160
Leu Leu Tyr Asp Leu Pro Glu Val Ile Asp Asp Leu Pro Leu Pro Pro
165 170 175
Leu Lys Asp Ser Phe Gln Thr Val Gln Cys Asn Cys Ser Val Arg Glu
180 185 190
Cys Glu Cys His Val Pro Val Pro Arg Ala Lys Val Asn Tyr Ala Leu
195 200 205
Leu Met Tyr Leu Glu Ile Thr Ser Ala Gly Val Ser Phe Gln Ser Pro
210 215 220
Leu Met Ser Leu Gln Pro Met Leu Val Val Lys Pro Asp Pro Pro Leu
225 230 235 240
Gly Leu Arg Met Glu Val Thr Asp Asp Gly Asn Leu Lys Ile Ser Trp
245 250 255
Asp Ser Gln Thr Lys Ala Pro Phe Pro Leu Gln Tyr Gln Val Lys Tyr
260 265 270
Leu Glu Asn Ser Thr Ile Val Arg Glu Ala Ala Glu Ile Val Ser Asp
275 280 285
Thr Ser Leu Leu Val Asp Ser Val Leu Pro Gly Ser Ser Tyr Glu Val
290 295 300
Gln Val Arg Ser Lys Arg Leu Asp Gly Ser Gly Val Trp Ser Asp Trp
305 310 315 320
Ser Leu Pro Gln Leu Phe Thr Thr Gln Asp Val Met Tyr Phe Pro Pro
325 330 335
Lys Ile Leu Thr Ser Val Gly Ser Asn Ala Ser Phe Cys Cys Ile Tyr
340 345 350
Lys Asn Glu Asn Gln Thr Ile Ser Ser Lys Gln Ile Val Trp Trp Met
355 360 365
Asn Leu Ala Glu Lys Ile Pro Glu Thr Gln Tyr Asn Thr Val Ser Asp
370 375 380
His Ile Ser Lys Val Thr Phe Ser Asn Leu Lys Ala Thr Arg Pro Arg
385 390 395 400
Gly Lys Phe Thr Tyr Asp Ala Val Tyr Cys Cys Asn Glu Gln Ala Cys
405 410 415
His His Arg Tyr Ala Glu Leu Tyr Val Ile Asp Val Asn Ile Asn Ile
420 425 430
Ser Cys Glu Thr Asp Gly Tyr Leu Thr Lys Met Thr Cys Arg Trp Ser
435 440 445
Pro Ser Thr Ile Gln Ser Leu Val Gly Ser Thr Val Gln Leu Arg Tyr
450 455 460
His Arg Arg Ser Leu Tyr Cys Pro Asp Asn Pro Ser Ile Arg Pro Thr
465 470 475 480
Ser Glu Leu Lys Asn Cys Val Leu Gln Thr Asp Gly Phe Tyr Glu Cys
485 490 495
Val Phe Gln Pro Ile Phe Leu Leu Ser Gly Tyr Thr Met Trp Ile Arg
500 505 510
Ile Asn His Ser Leu Gly Ser Leu Asp Ser Pro Pro Thr Cys Val Leu
515 520 525
Pro Asp Ser Val Val Lys Pro Leu Pro Pro Ser Asn Val Lys Ala Glu
530 535 540
Ile Thr Ile Asn Thr Gly Leu Leu Lys Val Ser Trp Glu Lys Pro Val
545 550 555 560
Phe Pro Glu Asn Asn Leu Gln Phe Gln Ile Arg Tyr Gly Leu Asn Gly
565 570 575
Lys Glu Ile Gln Trp Lys Thr His Glu Val Phe Asp Ala Lys Ser Lys
580 585 590
Ser Ala Ser Leu Pro Val Ser Asp Leu Cys Ala Val Tyr Val Val Gln
595 600 605
Val Arg Cys Arg Arg Leu Asp Gly Leu Gly Tyr Trp Ser Asn Trp Ser
610 615 620
Ser Pro Ala Tyr Thr Leu Val Met Asp Val Lys Val Pro Met Arg Gly
625 630 635 640
Pro Glu Phe Trp Arg Ile Met Asp Gly Asp Ile Thr Lys Lys Glu Arg
645 650 655
Asn Val Thr Leu Leu Trp Lys Pro Leu Met Lys Asn Asp Ser Leu Cys
660 665 670
Ser Val Arg Arg Tyr Val Val Lys His Arg Thr Ala His Asn Gly Thr
675 680 685
Trp Ser Gln Asp Val Gly Asn Gln Thr Asn Leu Thr Phe Leu Trp Ala
690 695 700
Glu Ser Ala His Thr Val Thr Val Leu Ala Ile Asn Ser Ile Gly Ala
705 710 715 720
Ser Leu Val Asn Phe Asn Leu Thr Phe Ser Trp Pro Met Ser Lys Val
725 730 735
Asn Ala Val Gln Ser Leu Ser Ala Tyr Pro Leu Ser Ser Ser Cys Val
740 745 750
Ile Leu Ser Trp Thr Leu Ser Pro Asn Asp Tyr Ser Leu Leu Tyr Leu
755 760 765
Val Ile Glu Trp Lys Asn Leu Asn Asp Asp Asp Gly Met Lys Trp Leu
770 775 780
Arg Ile Pro Ser Asn Val Asn Lys Tyr Tyr Ile His Asp Asn Phe Ile
785 790 795 800
Pro Ile Glu Lys Tyr Gln Phe Ser Leu Tyr Pro Val Phe Met Glu Gly
805 810 815
Val Gly Lys Pro Lys Ile Ile Asn Gly Phe Thr Lys Asp Asp Ile Ala
820 825 830
Lys Gln Gln Asn Asp Ala Gly Leu Tyr Val Ile Val Pro Ile Ile Ile
835 840 845
Ser Ser Cys Val Leu Leu Leu Gly Thr Leu Leu Ile Ser His Gln Arg
850 855 860
Met Lys Lys Leu Phe Trp Asp Asp Val Pro Asn Pro Lys Asn Cys Ser
865 870 875 880
Trp Ala Gln Gly Leu Asn Phe Gln Lys Pro Glu Thr Phe Glu His Leu
885 890 895
Phe Thr Lys His Ala Glu Ser Val Ile Phe Gly Pro Leu Leu Leu Glu
900 905 910
Pro Glu Pro Val Ser Glu Glu Ile Ser Val Asp Thr Ala Trp Lys Asn
915 920 925
Lys Asp Glu Met Val Pro Ala Ala Met Val Ser Leu Leu Leu Thr Thr
930 935 940
Pro Asp Ser Thr Arg Gly Ser Ile Cys Ile Ser Asp Gln Cys Asn Ser
945 950 955 960
Ala Asn Phe Ser Gly Ala Gln Ser Thr Gln Gly Thr Cys Glu Asp Glu
965 970 975
Cys Gln Ser Gln Pro Ser Val Lys Tyr Ala Thr Leu Val Ser Asn Val
980 985 990
Lys Thr Val Glu Thr Asp Glu Glu Gln Gly Ala Ile His Ser Ser Val
995 1000 1005
Ser Gln Cys Ile Ala Arg Lys His Ser Pro Leu Arg Gln Ser Phe Ser
1010 1015 1020
Ser Asn Ser Trp Glu Ile Glu Ala Gln Ala Phe Phe Leu Leu Ser Asp
025 1030 1035 1040
His Pro Pro Asn Val Ile Ser Pro Gln Leu Ser Phe Ser Gly Leu Asp
1045 1050 1055
Glu Leu Leu Glu Leu Glu Gly Asn Phe Pro Glu Glu Asn His Gly Glu
1060 1065 1070
Lys Ser Val Tyr Tyr Leu Gly Val Ser Ser Gly Asn Lys Arg Glu Asn
1075 1080 1085
Asp Met Leu Leu Thr Asp Glu Ala Gly Val Leu Cys Pro Phe Pro Ala
1090 1095 1100
His Cys Leu Phe Ser Asp Ile Arg Ile Leu Gln Glu Ser Cys Ser His
105 1110 1115 1120
Phe Val Glu Asn Asn Leu Asn Leu Gly Thr Ser Gly Lys Asn Phe Val
1125 1130 1135
Pro Tyr Met Pro Gln Phe Gln Ser Cys Ser Thr His Ser His Lys Ile
1140 1145 1150
Ile Glu Asn Lys Met Cys Asp Leu Thr Val
1155 1160






3650 base pairs


nucleic acid


single


linear




cDNA




not provided



2
TGGGGCAATT GGGCTGACCT TTCTTATGCT GGGATGTGCC TTGGAGGACT ATGGGTGTCT 60
ATCTCTGAAG TAAGATGACG TGTCAGAAAT TCTATGTGGT TTTGTTACAC TGGGAATTTC 120
TGTATGTGAT AACTGCACTT AACCTGGCCT ATCCAACCTC TCCCTGGAGA TTTAAGCTGT 180
TTTGTGCGCC ACCGAGTACA ACTGATGACT CCTTTCTCTC TCCTGCTGGA GTCCCAAACA 240
ATACTTCGTC TTTGAAGGGG GCTTCTGAAG CACTTGTTGA AGCTAAATTT AATTCAACTG 300
GTATCTACGT TTCTGAGTTA TCCAAAACCA TTTTCCACTG TTGCTTTGGG AATGAGCAAG 360
GTCAAAACTG CTCCGCACTC ACAGGCAACA CTGAAGGGAA GACGCTGGCT TCAGTGGTGA 420
AGCCTTTAGT TTTCCGCCAA CTAGGTGTAA ACTGGGACAT AGAGTGCTGG ATGAAAGGGG 480
ACTTGACATT ATTCATCTGT CATATGGAAC CATTACTTAA GAACCCCTTC AAGAATTATG 540
ACTCTAAGGT TCACCTTTTA TATGATCTGC CTGAAGTTAT AGATGATTTG CCTCTGCCCC 600
CACTGAAAGA CAGCTTTCAG ACTGTCCAGT GCAACTGCAG TGTTCGGGAA TGCGAATGTC 660
ATGTACCAGT ACCCAGAGCC AAAGTCAACT ACGCTCTTCT GATGTATTTA GAAATCACAT 720
CTGCTGGTGT GAGTTTTCAG TCACCTCTAA TGTCACTGCA GCCCATGCTT GTTGTGAAGC 780
CCGATCCACC GCTGGGTTTG CGTATGGAAG TCACAGATGA TGGTAATTTA AAGATTTCAT 840
GGGACAGCCA AACAAAAGCA CCATTTCCAC TTCAATATCA GGTGAAATAT TTAGAGAATT 900
CTACAATCGT AAGAGAGGCT GCTGAAATCG TCTCGGATAC ATCTCTGCTG GTAGACAGCG 960
TGCTTCCTGG GTCTTCATAC GAGGTCCAGG TGAGGAGCAA GAGACTGGAT GGCTCAGGAG 1020
TCTGGAGTGA CTGGAGTTTA CCTCAACTCT TTACCACACA AGATGTCATG TATTTTCCAC 1080
CCAAAATTCT GACGAGTGTT GGATCCAATG CTTCCTTTTG CTGCATCTAC AAAAATGAGA 1140
ACCAGACTAT CTCCTCAAAA CAAATAGTTT GGTGGATGAA TCTAGCCGAG AAGATCCCCG 1200
AGACACAGTA CAACACTGTG AGTGACCACA TTAGCAAAGT CACTTTCTCC AACCTGAAAG 1260
CCACCAGACC TCGAGGGAAG TTTACCTATG ATGCAGTGTA CTGCTGCAAT GAGCAGGCAT 1320
GCCATCACCG CTACGCTGAA TTATATGTGA TCGATGTCAA TATCAATATA TCATGTGAAA 1380
CTGACGGGTA CTTAACTAAA ATGACTTGCA GATGGTCACC CAGCACAATC CAATCACTAG 1440
TGGGAAGCAC TGTGCAGTTG AGGTATCACA GGCGCAGCCT GTACTGTCCC GATAATCCAT 1500
CTATTCGTCC TACATCAGAG CTCAAAAACT GCGTCTTACA GACAGATGGC TTTTATGAAT 1560
GTGTTTTCCA GCCAATCTTT CTATTATCTG GCTATACAAT GTGGATCAGG ATCAACCATT 1620
CTTTAGGTTC ACTTGACTCT CCACCAACGT GTGTCCTTCC TGACTCCGTA GTAAAACCAC 1680
TACCTCCATC TAATGTAAAA GCAGAGATTA CTATAAACAC TGGATTATTG AAAGTATCTT 1740
GGGAAAAGCC AGTCTTTCCA GAGAATAACC TTCAGTTCCA GATTCGATAT GGCTTAAATG 1800
GAAAAGAAAT ACAATGGAAG ACACACGAGG TATTCGATGC AAAATCAAAA TCGGCCAGCC 1860
TGCCAGTGTC AGATCTCTGT GCGGTCTATG TGGTACAGGT TCGCTGCCGG CGGTTGGATG 1920
GACTAGGGTA TTGGAGTAAT TGGAGCAGTC CAGCCTACAC TCTTGTCATG GATGTAAAAG 1980
TTCCTATGAG AGGGCCTGAA TTCTGGAGAA TAATGGATGG GGATATTACT AAAAAGGAGA 2040
GAAATGTCAC CTTGCTTTGG AAGCCACTGA TGAAAAATGA CTCACTGTGT AGTGTGAGGA 2100
GGTATGTGGT GAAGCATCGT ACTGCCCACA ATGGGACATG GTCACAAGAT GTGGGAAATC 2160
AGACCAATCT CACTTTCCTG TGGGCAGAAT CAGCACACAC TGTTACAGTT CTGGCCATCA 2220
ATTCCATCGG TGCCTCCCTT GTGAATTTTA ACCTTACGTT CTCATGGCCC ATGAGTAAAG 2280
TGAATGCTGT GCAGTCACTC AGTGCTTATC CCCTGAGCAG CAGCTGCGTC ATCCTTTCCT 2340
GGACACTGTC ACCTAATGAT TATAGTCTGT TATATCTGGT TATTGAATGG AAGAACCTTA 2400
ATGATGATGA TGGAATGAAG TGGCTTAGAA TCCCTTCGAA TGTTAACAAG TATTATATCC 2460
ATGATAATTT TATTCCTATC GAGAAATATC AGTTTAGTCT TTACCCAGTA TTTATGGAAG 2520
GAGTTGGAAA ACCAAAGATA ATTAATGGTT TCACCAAAGA TGATATCGCC AAACAGCAAA 2580
ATGATGCAGG GCTGTATGTC ATTGTACCGA TAATTATTTC CTCTTGTGTC CTGCTGCTCG 2640
GAACACTGTT AATTTCACAC CAGAGAATGA AAAAGTTGTT TTGGGACGAT GTTCCAAACC 2700
CCAAGAATTG TTCCTGGGCA CAAGGACTTA ATTTCCAAAA GCCTGAAACA TTTGAGCATC 2760
TTTTTACCAA GCATGCAGAA TCAGTGATAT TTGGTCCTCT TCTTCTGGAG CCTGAACCAG 2820
TTTCAGAAGA AATCAGTGTC GATACAGCTT GGAAAAATAA AGATGAGATG GTACCAGCAG 2880
CTATGGTCTC ACTTCTTTTG ACCACTCCAG ATTCCACAAG GGGTTCTATT TGTATCAGTG 2940
ACCAGTGTAA CAGTGCTAAC TTCTCTGGGG CTCAGAGCAC CCAGGGAACC TGTGAGGATG 3000
AGTGTCAGAG TCAACCCTCA GTTAAATATG CAACGCTGGT CAGCAACGTG AAAACAGTGG 3060
AAACTGATGA AGAGCAAGGG GCTATACATA GTTCTGTCAG CCAGTGCATC GCCAGGAAAC 3120
ATTCCCCACT GAGACAGTCT TTTTCTAGCA ACTCCTGGGA GATAGAGGCC CAGGCATTTT 3180
TCCTTTTATC AGATCATCCA CCCAATGTGA TTTCACCACA ACTTTCATTC TCAGGGTTGG 3240
ATGAGCTTTT GGAACTGGAG GGAAATTTTC CTGAAGAAAA TCACGGGGAA AAATCTGTGT 3300
ATTATCTAGG AGTCTCCTCA GGAAACAAAA GAGAGAATGA TATGCTTTTG ACTGATGAGG 3360
CAGGGGTATT GTGCCCATTC CCAGCTCACT GTCTGTTCAG TGACATCAGA ATCCTCCAGG 3420
AGAGTTGTTC ACACTTTGTA GAAAATAATT TGAATTTAGG GACCTCTGGT AAGAACTTTG 3480
TACCTTACAT GCCCCAGTTT CAATCCTGTT CCACTCACAG TCATAAGATA ATAGAAAATA 3540
AGATGTGTGA CTTAACTGTG TAATCTTGTC CAAAAACTTC CAGGTTCCAT TCCAGTAGAG 3600
TGTGTCATGT ATAATATGTT CTTTTATAGT TGTGGGTGGG AGAGAAAGCC 3650






19 base pairs


nucleic acid


single


linear




cDNA




not provided



3
ATGATGTGYC ARAARTTYT 19






20 base pairs


nucleic acid


single


linear




cDNA




not provided



4
CAYTGGGART TYCTTTAYGT 20






17 base pairs


nucleic acid


single


linear




cDNA




not provided



5
GARTGYTGGA TGAARGG 17






18 base pairs


nucleic acid


single


linear




cDNA




not provided



6
AARCARATTG TTTGGTGG 18






17 base pairs


nucleic acid


single


linear




cDNA




not provided



7
GGTTAYACTA TGTGGAT 17






17 base pairs


nucleic acid


single


linear




cDNA




not provided



8
ATCCACATTG TRTATCC 17






20 base pairs


nucleic acid


single


linear




cDNA




not provided



9
CTCCARTTRC TCCARTATCC 20






17 base pairs


nucleic acid


single


linear




cDNA




not provided



10
ACYTTRCTCA TTGGCCA 17






18 base pairs


nucleic acid


single


linear




cDNA




not provided



11
CCAYTTCATT CCRTCRTC 18






21 base pairs


nucleic acid


single


linear




cDNA




not provided



12
CTGCACTTAA CCTGGCCTAT C 21






21 base pairs


nucleic acid


single


linear




cDNA




not provided



13
GATAGGCCAG GTTAAGTGCA G 21






20 base pairs


nucleic acid


single


linear




cDNA




not provided



14
GAGTGCGGAG CAGTTTTGAC 20






22 base pairs


nucleic acid


single


linear




cDNA




not provided



15
GTCTCGGATA CATCTCTGCT GG 22






19 base pairs


nucleic acid


single


linear




cDNA




not provided



16
GATTGGATTG TGCTGGGTG 19






19 base pairs


nucleic acid


single


linear




cDNA




not provided



17
TCACCTTGCT TTGGAAGCC 19






21 base pairs


nucleic acid


single


linear




cDNA




not provided



18
GACATGGTCA CAAGATGTGG G 21






21 base pairs


nucleic acid


single


linear




cDNA




not provided



19
GGCCAGAACT GTAACAGTGT G 21






21 base pairs


nucleic acid


single


linear




cDNA




not provided



20
CGCCAACTAG GTGTAAACTG G 21






20 base pairs


nucleic acid


single


linear




cDNA




not provided



21
TGACTTCCAT ACGCAAACCC 20






20 base pairs


nucleic acid


single


linear




cDNA




not provided



22
GAAGCACTGT GCAGTTGAGG 20






21 base pairs


nucleic acid


single


linear




cDNA




not provided



23
GGAAGACACA CGAGGTATTC G 21






21 base pairs


nucleic acid


single


linear




cDNA




not provided



24
CCAGAGCCAA AGTCAACTAC G 21






21 base pairs


nucleic acid


single


linear




cDNA




not provided



25
CCTGGACACT GTCACCTGAT G 21






21 base pairs


nucleic acid


single


linear




cDNA




not provided



26
CATYTCRTCY TTRTTYTTCC A 21






20 base pairs


nucleic acid


single


linear




cDNA




not provided



27
TCRCACATYT TRTTYTTCCA 20






17 base pairs


nucleic acid


single


linear




cDNA




not provided



28
AAYTGTGGCA TRTATCC 17






21 base pairs


nucleic acid


single


linear




cDNA




not provided



29
GTTTGCGTAT GGAAGTCACA G 21






21 base pairs


nucleic acid


single


linear




cDNA




not provided



30
ACCAGCAGAG ATGTATCCGA G 21






18 base pairs


nucleic acid


single


linear




cDNA




not provided



31
CTGCTGCTCG GAACACTG 18






21 base pairs


nucleic acid


single


linear




cDNA




not provided



32
AAGTGAGACC ATAGCTGCTG G 21






19 base pairs


nucleic acid


single


linear




cDNA




not provided



33
CTTCTGAAGC CCGATCCAC 19






28 base pairs


nucleic acid


single


linear




cDNA




not provided



34
GGGACAAAAT TACACAGTTA ATTCACAC 28






21 base pairs


nucleic acid


single


linear




cDNA




not provided



35
AATGACATAC AGCCCTGCAT C 21






19 base pairs


nucleic acid


single


linear




cDNA




not provided



36
TTGGAGGACT ATGGGTGTC 19






19 base pairs


nucleic acid


single


linear




cDNA




not provided



37
GAACAGGATT GAAAGTGGG 19






19 base pairs


nucleic acid


single


linear




cDNA




not provided



38
CTACTGGAAT GGAACCTGG 19






21 base pairs


nucleic acid


single


linear




cDNA




not provided



39
GGGAATGCGA ATGTCATGTA C 21






20 base pairs


nucleic acid


single


linear




cDNA




not provided



40
AGCCATCCAG TCTCTTGCTC 20






19 base pairs


nucleic acid


single


linear




cDNA




not provided



41
CACCCAGCAC AATCCAATC 19






21 base pairs


nucleic acid


single


linear




cDNA




not provided



42
GCCATATCGA ATCTGGAACT G 21






21 base pairs


nucleic acid


single


linear




cDNA




not provided



43
ATGATGATGG AATGAAGTGG C 21






20 base pairs


nucleic acid


single


linear




cDNA




not provided



44
GATGCACTGG CTGACAGAAC 20






20 base pairs


nucleic acid


single


linear




cDNA




not provided



45
GTTCTGTCAG CCAGTGCATC 20






21 base pairs


nucleic acid


single


linear




cDNA




not provided



46
TGACTTTGGC TCTGGGTACT G 21






20 base pairs


nucleic acid


single


linear




cDNA




not provided



47
TTCTCCAGAA TTCAGGCCCT 20






20 base pairs


nucleic acid


single


linear




cDNA




not provided



48
GGAGCCTGAA CCAGTTTCAG 20






19 base pairs


nucleic acid


single


linear




cDNA




not provided



49
TTTGACTGAT GAGGCAGGG 19






18 base pairs


nucleic acid


single


linear




cDNA




not provided



50
CTTATGCTGG GATGTGCC 18






19 base pairs


nucleic acid


single


linear




cDNA




not provided



51
TCGTGGCATT ATCCTTCAG 19






20 base pairs


nucleic acid


single


linear




cDNA




not provided



52
TCTCTCCCAC CCACAACTAT 20






24 base pairs


nucleic acid


single


linear




cDNA




not provided



53
CATCATYTCR TCYTTRTTYT TCCA 24






17 base pairs


nucleic acid


single


linear




cDNA




not provided



54
GTYTGRAAYT GTGGCAT 17






20 base pairs


nucleic acid


single


linear




cDNA




not provided



55
TCRCACATYT TRTTYTCCAT 20






20 base pairs


nucleic acid


single


linear




cDNA




not provided



56
GTTCTGCAAA TCCAGGTGTA 20






20 base pairs


nucleic acid


single


linear




cDNA




not provided



57
TGGGTTCATC TGTAGTGGTC 20






68 amino acids


amino acid


single


linear




protein




not provided



58
Ser Val Ile Ile Leu Lys Tyr Asn Ile Gln Tyr Arg Thr Lys Asp Ala
1 5 10 15
Ser Thr Trp Ser Gln Ile Pro Pro Glu Asp Thr Ala Ser Thr Arg Ser
20 25 30
Ser Phe Thr Val Gln Asp Leu Lys Pro Phe Thr Glu Tyr Val Phe Arg
35 40 45
Ile Arg Cys Met Lys Glu Asp Gly Lys Gly Tyr Trp Ser Asp Trp Ser
50 55 60
Glu Glu Ala Ser
65






75 amino acids


amino acid


single


linear




protein




not provided



59
Asn Leu Lys Ile Ser Trp Asp Ser Gln Thr Lys Ala Pro Phe Pro Leu
1 5 10 15
Gln Tyr Gln Val Lys Tyr Leu Glu Asn Ser Thr Ile Val Arg Glu Ala
20 25 30
Ala Glu Ile Val Ser Asp Thr Ser Leu Leu Val Asn Ser Val Leu Pro
35 40 45
Gly Ser Ser Tyr Glu Val Gln Val Arg Ser Lys Arg Leu Asp Gly Ser
50 55 60
Gly Val Trp Ser Asp Trp Ser Leu Pro Gln Leu
65 70 75






75 amino acids


amino acid


single


linear




protein




not provided



60
Asn Leu Lys Ile Ser Trp Asp Ser Gln Thr Met Ala Pro Phe Pro Leu
1 5 10 15
Gln Tyr Gln Val Lys Tyr Leu Glu Asn Ser Thr Ile Val Arg Glu Ala
20 25 30
Ala Glu Ile Val Ser Ala Thr Ser Leu Leu Val Asp Ser Val Leu Pro
35 40 45
Gly Ser Ser Tyr Glu Val Gln Val Arg Ser Lys Arg Leu Asp Gly Ser
50 55 60
Gly Val Trp Ser Asp Trp Ser Ser Pro Gln Val
65 70 75






76 amino acids


amino acid


single


linear




protein




not provided



61
Asn Leu Lys Ile Ser Trp Ser Ser Pro Pro Leu Val Pro Phe Pro Leu
1 5 10 15
Gln Tyr Gln Val Lys Tyr Ser Glu Asn Ser Thr Thr Val Ile Arg Glu
20 25 30
Ala Asp Lys Ile Val Ser Ala Thr Ser Leu Leu Val Asp Ser Ile Leu
35 40 45
Pro Gly Ser Ser Tyr Glu Val Gln Val Arg Gly Lys Arg Leu Asp Gly
50 55 60
Pro Gly Ile Trp Ser Asp Trp Ser Thr Pro Arg Val
65 70 75






77 amino acids


amino acid


single


linear




protein




not provided



62
Leu Leu Lys Val Ser Trp Glu Lys Pro Val Phe Pro Glu Asn Asn Leu
1 5 10 15
Gln Phe Gln Ile Arg Tyr Gly Leu Asn Gly Lys Glu Ile Gln Trp Lys
20 25 30
Thr His Glu Val Phe Asp Ala Lys Ser Lys Ser Ala Ser Leu Pro Val
35 40 45
Ser Asp Leu Cys Ala Val Tyr Val Val Gln Val Arg Cys Arg Arg Leu
50 55 60
Asp Gly Leu Gly Tyr Trp Ser Asn Trp Ser Ser Pro Ala
65 70 75






77 amino acids


amino acid


single


linear




protein




not provided



63
Leu Leu Lys Val Ser Trp Glu Lys Pro Val Phe Pro Glu Asn Asn Leu
1 5 10 15
Gln Phe Gln Ile Arg Tyr Gly Leu Ser Gly Lys Glu Ile Gln Trp Lys
20 25 30
Thr His Glu Val Phe Asp Ala Lys Ser Lys Ser Ala Ser Leu Leu Val
35 40 45
Ser Asp Leu Cys Ala Val Tyr Val Val Gln Val Arg Cys Arg Arg Leu
50 55 60
Asp Gly Leu Gly Tyr Trp Ser Asn Trp Ser Ser Pro Ala
65 70 75






77 amino acids


amino acid


single


linear




protein




not provided



64
Leu Leu Lys Ile Ser Trp Glu Lys Pro Val Phe Pro Glu Asn Asn Leu
1 5 10 15
Gln Phe Gln Ile Arg Tyr Gly Leu Ser Gly Lys Glu Val Gln Trp Lys
20 25 30
Met Tyr Glu Val Tyr Asp Ala Lys Ser Lys Ser Val Ser Leu Pro Val
35 40 45
Pro Asp Leu Cys Ala Val Tyr Ala Val Gln Val Arg Cys Lys Arg Leu
50 55 60
Asp Gly Leu Gly Tyr Trp Ser Asn Trp Ser Asn Pro Ala
65 70 75






40 amino acids


amino acid


single


linear




peptide




not provided



65
Leu Lys Ile Ser Trp Ser Pro Asn Leu Gln Tyr Gln Lys Tyr Asn Val
1 5 10 15
Glu Ala Ser Val Pro Tyr Val Gln Val Arg Cys Lys Arg Leu Asp Gly
20 25 30
Gly Tyr Trp Ser Asp Trp Ser Pro
35 40






7 amino acids


amino acid


single


linear




protein




not provided



66
Gly Xaa Trp Ser Xaa Trp Ser
1 5






5 amino acids


amino acid


single


linear




protein




not provided



67
Trp Ser Xaa Trp Ser
1 5






24 base pairs


nucleic acid


single


linear




cDNA




not provided



68
AGAGCGGACA CTCTTTGAAT ATCT 24






5 amino acids


amino acid


single


linear




protein




not provided



69
Arg Ala Asp Thr Leu
1 5






7 amino acids


amino acid


single


linear




protein




not provided



70
His Trp Glu Phe Leu Tyr Val
1 5






6 amino acids


amino acid


single


linear




protein




not provided



71
Glu Cys Trp Met Lys Gly
1 5






6 amino acids


amino acid


single


linear




protein




not provided



72
Gly Tyr Thr Met Trp Ile
1 5






7 amino acids


amino acid


single


linear




protein




not provided



73
Val Tyr Trp Ser Asn Trp Ser
1 5






6 amino acids


amino acid


single


linear




protein




not provided



74
Trp Pro Met Ser Lys Val
1 5






8 amino acids


amino acid


single


linear




protein




not provided



75
Trp Lys Asn Lys Asp Glu Met Met
1 5






6 amino acids


amino acid


single


linear




protein




not provided



76
Met Pro Gln Phe Gln Thr
1 5






7 amino acids


amino acid


single


linear




protein




not provided



77
Met Glu Asn Lys Met Cys Asp
1 5







Claims
  • 1. An isolated nucleic acid encoding a rat ob-receptor (OB-R), said receptor comprising the sequence of SEQ ID NO:1.
  • 2. A nucleic acid according to claim 1 which is a DNA.
  • 3. A vector comprising a nucleic acid in accordance with claim 1.
  • 4. A vector according to claim 3 which is a plasmid.
  • 5. A vector according to claim 3 which is a viral vector.
  • 6. A host cell containing a vector according to claim 3.
  • 7. A host cell according to claim 6 which is E. coli, a mammalian cell, or a yeast cell.
  • 8. An isolated nucleic acid in accordance with claim 1 wherein said nucleic acid comprises the sequence of SEQ ID NO:2 from nucleotide 75 to nucleotide 3563.
  • 9. A vector comprising a nucleic acid in accordance with claim 8.
  • 10. A host cell comprising the vector of claim 9.
  • 11. An isolated DNA encoding fa OB-R said DNA comprising the sequence of SEQ ID NO:2 wherein nucleotide 880 is a C instead of an A.
  • 12. A vector comprising a DNA in accordance with claim 11.
  • 13. A host cell comprising the vector of claim 12.
  • 14. An isolated nucleic acid encoding a rat fa ob-receptor (OB-R), said receptor comprising the sequence of SEQ ID NO:1 wherein amino acid 269 is a proline instead of a glutamine.
  • 15. A vector comprising a nucleic acid in accordance with claim 14.
  • 16. A host cell comprising the vector of claim 15.
Parent Case Info

This application claims benefit of Provisional Appln. 60/013,969 filed Mar. 22, 1996.

US Referenced Citations (1)
Number Name Date Kind
5643748 Snodgrass et al. Jul 1997
Foreign Referenced Citations (3)
Number Date Country
WO 9608510 Mar 1996 WO
WO 9635787 Nov 1996 WO
9726335 Jul 1997 WO
Non-Patent Literature Citations (16)
Entry
Iida et al BBRC 222 1996, p. 19-26.*
Bennett et al, Current Biology 6(9) 1996, p. 1170-80.*
Phillips, Michael S., et al. “Leptin receptor missense mutation in the fatty Zucker rat”, 1996, Nature Genetics, vol. 13, No. 1, pp. 18-19.
Murakami, Takashi, et al. “Cloning of Rat Obese cDNA and its Expression in Obese Rats+”, 1995 Biochem and Biophy., No. 3, pp. 944-952.
Guan et al., “Differential Expression of mRNA for Leptin Receptor Isoforms in the Rat Brain”, Molec. and Cell Endocrinology, vol. 133, pp. 1-7, 1997.
Chen et al. “Evidence That the Diabetes Gene Encodes the Leptin Receptor: Identification of a Mutation in the Leptin Receptor Gene in db/db Mice,” 1996 Cell 84:491-495.
Chua et al. “Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor,” 1996 Science 271:994-996.
Chua et al. “Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr),” 1996 Diabetes 45:1141-1143.
Lee et al. “Abnormal splicing of the leptin receptor in diabetic mice”, 1996 Nature 379:632-635.
Phillips et al. “Leptin receptor missense mutation in the fatty Zucket rat”, 1996 Nature Genetics 13:19-20.
Rosenblum et al. “Functional STAT 1 and 3 signaling by the leptin receptor (OB-R): reduced expression of the rat fatty leptin receptor in transfected cells”, 1996 Endocrinology 137:5178-5181.
Spiegelman et al. “Adipogenesis and Obesity: Rounding out the big picture”, 1996 Cell 87:377-389.
Stephens et al. “The role of neuropeptide Y in the antiobesity action of the obese gene product”, 1995 Nature 377:530-532.
Takaya et al. “Molecular cloning of rat leptin receptor isoform complementary DNAs—identification of a missense mutation in Zucker fatty (fa/fa) rats”, 1996 Biochem Biophys Res Comm 225:75-83.
Tartaglia et al. “Identification and Expression Cloning of a Leptin Receptor, OB-R”, 1995 Cell 83:1263-1271.
Wang et al. “A novel leptin receptor isoform in rat”, 1996 FEBS Lett. 392:87-90.
Provisional Applications (1)
Number Date Country
60/013969 Mar 1996 US